Старонка 1 ад 122 вынікі
FIELD OF INVENTION
The present invention relates to phospholipid compositions and uses thereof.
BACKGROUND OF THE INVENTION
Neurodegeneration in Alzheimer's disease (AD) is associated with the accumulation of extracellular plaques of small peptides, called amyloid-.beta. (A.beta.), and intracellular
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to unique formulations for treating inflammatory bowel disease (IBD), such as ulcerative colitis, including 5-amino salicylic acid (5ASA) and a phospholipid.
The present invention relates to unique compositions of
RELATED APPLICATIONS
This application claims priority to U.S. patent application Ser. No. 11/880,059, entitled "PREPARATIONS OF PHOSPHOLIPIDS AND PHARMACEUTICALS CONTAINING 5-AMINO SALICYLIC ACID FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE," filed Jul. 19, 2007 now U.S. Pat. No. 7,700,651, which
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to pharmacology and, more particularly, but not exclusively, to a novel methodology for the treatment of inflammatory bowel diseases.
Inflammatory bowel disease, or IBD, is a collective term
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention relates to high purity associated complexes of a phospholipid (PL) and a selective and/or nonselective non-steroidal, anti-inflammatory drug (sns-NSAID) and to methods for making and using same. The present invention also
FIELD OF THE INVENTION
The present invention relates to compounds comprising non-steroidal anti-inflammatory drugs (NSAIDs) covalently linked to a phospholipid moiety via a bridging group, to pharmaceutical compositions comprising such compounds and to the use thereof for the treatment of diseases
FIELD OF THE INVENTION
The present invention relates to compounds comprising non-steroidal anti-inflammatory drugs (NSAIDs) covalently linked to a phospholipid moiety via a bridging group, to pharmaceutical compositions comprising such compounds and to the use thereof for the treatment of diseases
FIELD OF THE INVENTION
The present invention relates to compounds comprising non-steroidal anti-inflammatory drugs (NSAIDs) covalently linked to a phospholipid moiety via a bridging group, to pharmaceutical compositions comprising such compounds and to the use thereof for the treatment of diseases
TECHNICAL FIELD
The present disclosure relates to lipid compounds of the general formula (I):
##STR00001## wherein R.sub.1 is a C.sub.10-C.sub.22 alkyl group, a C.sub.10-C.sub.22 alkenyl group having 1-6 double bonds, or a C.sub.10-C.sub.22 alkynyl group having 1-6 triple bonds; R.sub.2 and R.sub.3
FIELD OF THE INVENTION
The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.
BACKGROUND OF THE INVENTION
Genetic traits, coupled with a Western diet
FIELD OF THE INVENTION
The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.
BACKGROUND OF THE INVENTION
Genetic traits, coupled with a Western diet
FIELD OF THE INVENTION
The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.
BACKGROUND OF THE INVENTION
Genetic traits, coupled with a Western diet
FIELD OF THE INVENTION
The invention relates to concentrated therapeutic compositions. More particularly, the invention relates to concentrated therapeutic phospholipid compositions useful for treating or preventing diseases.
BACKGROUND OF THE INVENTION
Genetic traits, coupled with a Western diet
The present invention concerns new substituted aminoalkanol phospholipids and methods for using the same.
The compounds of the invention correspond to the general formula I ##STR2## wherein X represents an oxygen or a sulphur atom and Y represents the radical --NR.sup.1 R.sup.2 or --OR.sup.3,
This invention relates to hydroxy-, alkoxy- and benzyloxy-substituted phospholipids. More particularly, this invention relates to alkylphospholipids of the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen, substituted and unsubstituted phenyl radicals, and